Cross-protective efficacy and safety of an adenovirus-based universal influenza vaccine expressing nucleoprotein, hemagglutinin, and the ectodomain of matrix protein 2
Vaccine·
- DOI
- 10.1016/j.vaccine.2024.04.054
- PMID
- 38714444
- PMCID
- —
- OpenAlex
- W4396665817
- Study type
- Journal article
- Publisher
- Elsevier BV
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The paper presents preclinical evidence for a broad influenza vaccine strategy that could be relevant to seasonal and pandemic influenza preparedness. Its relevance is limited to an animal model and does not establish clinical performance.
Structured evidence summary
Research question
The study asked which dose and administration route best support the efficacy and safety of a recombinant adenovirus-based influenza vaccine mixture, and whether it can cross-protect against different influenza strains in mice.
Study design
This was a preclinical mouse study of a recombinant adenovirus vaccine mixture given by intranasal or intramuscular route. It included dose-finding, influenza challenge experiments, and single and repeated toxicity assessments.
Population and setting
The setting was immunized mice in an experimental laboratory model. The challenges described included pH1N1, H3N2, and H5N1 influenza infections.
Main findings
The abstract reports that intranasal delivery was the preferred route for a 10^7 pfu vaccine mixture and was effective despite pre-existing adenovirus immunity. A 10^6 pfu dose produced higher anti-nucleoprotein antibody levels than the same dose of rAd/NP alone and protected mice from morbidity and mortality after lethal influenza challenge with pH1N1, H3N2, and H5N1. No noticeable adverse effects were seen in the toxicity studies.
Public-health relevance
The paper presents preclinical evidence for a broad influenza vaccine strategy that could be relevant to seasonal and pandemic influenza preparedness. Its relevance is limited to an animal model and does not establish clinical performance.
Important limitations
No explicit study limitations are stated in the supplied abstract. This summary is limited to the single provided abstract and metadata, so the original paper would be needed for decision-grade interpretation.
GIDS interpretation
This item is discoverable as a preclinical influenza vaccine study with cross-protection and safety endpoints. The supplied abstract supports context about a candidate vaccine approach, but not a live surveillance signal or clinical effectiveness.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 11 auditable classifier relationships to diseases, places, topics, and study design.